Pharma companies’ spend on lobbying nearly touches record high in US

By PharmaCompass

2019-04-25

Impressions: 133 Article

Last month, we had reported on Richard Francis stepping down as the CEO of Sandoz. He had said he is unable to “commit to (Sandoz’s) multi-year journey”.

While one Richard put in his papers, Novartis CEO Vas Narasimhan brought in another Richard to take his place. Narasimhan has tapped a GSK digital lead — Richard Saynor — to take over as CEO of Sandoz by August 1, 2019. Saynor is currently senior vice president of classic and established products as well as commercial and digital platforms at GSK.

Saynor will be seeing through Sandoz’s “multi-year transformation” that focuses on turning the generic player into a standalone unit within Novartis. This transformation is targeted at giving Sandoz “the right capabilities and the right freedom to operate in order to be successful,” Narasimhan said last week. Saynor’s appointment also fits into Narasimhan’s larger digital ambitions for Novartis.

The new chief is no stranger to Sandoz—he once held commercial leadership roles at the generics unit and oversaw its expansion in Asia, Latin America and Turkey.

Saynor will also become a member of Novartis’ executive committee. However, his appointment may not be enough to stop rumors that Novartis is considering offloading Sandoz, which posted declining sales during the latest quarter. The group has already spun off the Alcon eye-care business and is largely focusing on innovative drugs.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass